Last $1.03 USD
Change Today 0.00 / 0.00%
Volume 615.9K
PVCT On Other Exchanges
Symbol
Exchange
NYSE Amex
As of 4:15 PM 07/10/14 All times are local (Market data is delayed by at least 15 minutes).

provectus biopharmaceutica-a (PVCT) Snapshot

Open
$1.01
Previous Close
$1.03
Day High
$1.09
Day Low
$1.01
52 Week High
01/23/14 - $6.03
52 Week Low
05/27/14 - $0.30
Market Cap
178.3M
Average Volume 10 Days
917.9K
EPS TTM
$-0.22
Shares Outstanding
173.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PROVECTUS BIOPHARMACEUTICA-A (PVCT)

Related News

No related news articles were found.

provectus biopharmaceutica-a (PVCT) Related Businessweek News

No Related Businessweek News Found

provectus biopharmaceutica-a (PVCT) Details

Provectus Biopharmaceuticals, Inc., a development-stage biopharmaceutical company, is engaged in developing pharmaceuticals for oncology and dermatology indications. The company’s product line includes PV-10, which has completed Phase II study for metastatic melanoma; completed a Phase I study for breast cancer; and is in Phase I protocol expansion for liver metastasis, as well as initiated a Phase I feasibility study to detect immune cell infiltration into melanomas. It is also developing PH-10 that is in Phase IIc randomized study for the treatment of psoriasis; and has completed Phase II study for the treatment of atopic dermatitis. In addition, the company develops PH-10 for the treatment of actinic keratosis and severe acne vulgaris. Further, it is developing over-the-counter pharmaceuticals, including GloveAid, a hand cream with antiperspirant and antibacterial properties; Pure-ific line of products to prevent the spread of germs on skin; and Pure-Stick and Pure N Clear acne products. Additionally, Provectus Biopharmaceuticals, Inc. develops medical device technologies for markets comprising cosmetic treatments, such as reduction of wrinkles and elimination of spider veins, and other cosmetic blemishes; and therapeutic uses, including photoactivation of PH-10, other prescription drugs, and non-surgical destruction of certain skin cancers. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.

4 Employees
Last Reported Date: 05/8/14
Founded in 2002

provectus biopharmaceutica-a (PVCT) Top Compensated Officers

Chairman, Chief Executive Officer, Chief Exec...
Total Annual Compensation: $500.0K
President, Director, President of Xantech and...
Total Annual Compensation: $500.0K
Chief Operating Officer, Chief Financial Offi...
Total Annual Compensation: $500.0K
Chief Technology Officer and Executive Vice P...
Total Annual Compensation: $500.0K
Compensation as of Fiscal Year 2013.

provectus biopharmaceutica-a (PVCT) Key Developments

Provectus Biopharmaceuticals, Inc. Approves Amendment to its Certificate of Incorporation

Provectus Biopharmaceuticals, Inc. approved amendment to its Certificate of Incorporation, at the annual meeting of stockholders held on June 16, 2014.

The Rosen Law Firm Announces Filing of Securities Fraud Class Action Against Provectus Biopharmaceuticals, Inc

The Rosen Law Firm announced that a class action lawsuit has been filed on behalf of all purchasers of the securities of Provectus Biopharmaceuticals, Inc. during the period between December 17, 2013 and May 22, 2014, seeking to recover investors' losses. According to the lawsuit, defendants misrepresented and/or failed to disclose the true prospects for its PV-10 skin cancer drug. On January 23, 2014, Adam Feuerstein published an article on TheStreet.com alleging that Provectus management had misled investors about the potential for PV-10, questioning why the promised Phase 3 randomized controlled trial of PV-10 have not commenced and speculating that PV-10 may be obsolete in light of new skin cancer drugs being developed. On this news, Provectus stock fell $3.35 per share, or over 64%, on unusually heavy volume to close at $1.87 per share on January 23, 2014, damaging investors.

Provectus Biopharmaceuticals, Inc. - Special Call

To discuss the outline of the company's proposed phase 3 study of PV-10 in the treatment of melanoma, developments in the use of PV-10 in other cancer indications, as well as PH-10 and news regarding its use and to discuss potential plans to monetize its PV-10 and PH-10 assets with various contemplated license and co-development transactions

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PVCT:US $1.03 USD 0.00

PVCT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PVCT.
View Industry Companies
 

Industry Analysis

PVCT

Industry Average

Valuation PVCT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 12.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PROVECTUS BIOPHARMACEUTICA-A, please visit www.pvct.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.